



The Illinois Medical Bulletin



The Deleterious Impact of Tobacco Smoking on the Risk and Clinical Course of Crohn's Disease: A Review of the Evidence

¹A.Broughton, ²A. Brown

^{1,2} University of Illinois College of Medicine

Corresponding Email : broughtonmd183737@gmail.com

Article History :

Received date : 2016/10/12
Revised date : 2016/11/28
Accepted date : 2016/12/09
Published date : 2017/01/13



Copyright: © by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (BY NC) license (<https://creativecommons.org/licenses/by-nc/4.0/>).

ABSTRACT

Introduction: Crohn's disease is a chronic, transmural inflammatory bowel disease of unknown etiology. A number of genetic and environmental factors are implicated in its pathogenesis, but tobacco smoking has been identified as the single most important and consistently detrimental modifiable environmental risk factor.

Literature Review: A review of the pivotal scientific literature reveals a profoundly negative association between smoking and all aspects of Crohn's disease. Epidemiological studies consistently demonstrated that active smoking approximately doubles the risk of developing the disease. In patients with established Crohn's disease, smoking is strongly associated with a more severe and complicated disease course, including a higher likelihood of requiring immunosuppressive and biologic therapies and an increased risk of developing fibrostenotic and penetrating complications. Furthermore, smoking has been proven to significantly impair the response to medical treatments, including anti-TNF agents. It is also the most powerful predictor of disease recurrence following intestinal resection. Conversely, smoking cessation has been shown to be a beneficial therapeutic intervention.

Conclusion: The body of evidence confirms an unequivocal and causal link between tobacco smoking and adverse outcomes in Crohn's disease. Smoking acts as both a trigger for the disease and an accelerator of its progression. This establishes smoking cessation as a critical, non-negotiable component of comprehensive care for every patient with Crohn's disease.

Keywords: Crohn's Disease, Inflammatory Bowel Disease (IBD), Smoking, Tobacco, Risk Factor, Disease Progression.

INTRODUCTION

Inflammatory Bowel Disease (IBD) is a term for two chronic, idiopathic inflammatory conditions of the gastrointestinal tract: Ulcerative Colitis and Crohn's Disease. While they share some features, their relationship with environmental risk factors can be strikingly different. This is most evident with tobacco smoking, which presents a remarkable medical paradox: it appears to have a protective effect in ulcerative colitis, while it is profoundly and unequivocally harmful in Crohn's disease.

Crohn's disease is a transmural inflammatory process that can affect any part of the gastrointestinal tract from the mouth to the anus. It is characterized by a relapsing and remitting course and can lead to serious complications such as intestinal strictures, fistulas, and abscesses, often requiring surgery. Given the significant morbidity associated with the disease, the identification of modifiable risk factors is of paramount clinical importance. This literature review will synthesise the pivotal evidence that has firmly established tobacco smoking as the most significant environmental factor that negatively influences the risk and clinical course of Crohn's disease.

LITERATURE REVIEW

The scientific evidence detailing the harmful effects of smoking on Crohn's disease is extensive and consistent across epidemiological studies, clinical outcome research, and investigations into treatment response.

First, smoking has been established as a primary, independent risk factor for the development of Crohn's disease. Large case-control and cohort studies have consistently demonstrated that active smokers have approximately a twofold higher risk of being diagnosed with Crohn's disease compared to non-smokers. A clear dose-response relationship has also been described, with the risk increasing with the number of cigarettes smoked per day. This strong

epidemiological link points to smoking as a key trigger in genetically susceptible individuals (Mahid et al., 2006).

Beyond its role in disease initiation, smoking has a major negative impact on the clinical course and phenotype of established Crohn's disease. A large body of research has shown that patients with Crohn's disease who smoke experience a more aggressive and complicated form of the illness. Compared to non-smoking patients, smokers are more likely to have disease located in the small bowel, are more prone to developing fibrostenotic (stricturing) and penetrating (fistulizing) complications, and have a greater overall need for corticosteroids and immunosuppressive medications to control their disease (Cosnes et al., 2004).

Furthermore, smoking has been shown to significantly undermine the efficacy of medical therapies for Crohn's disease. This is a critical clinical finding, as it means smokers may not derive the full benefit from potent and expensive medications. Studies have demonstrated that smokers have a poorer response to both conventional immunosuppressants, like azathioprine, and to the powerful biologic agents that target Tumor Necrosis Factor-alpha (TNF- α), such as infliximab. Smokers often require dose escalation or switch to other therapies more frequently than non-smokers due to loss of response (Louis et al., 2003).

Perhaps the most powerful evidence of smoking's detrimental effect is seen in the post-operative setting. A large proportion of patients with Crohn's disease will eventually require surgery to resect a segment of diseased bowel. Disease recurrence at the site of the surgical anastomosis is very common. The single strongest predictor of post-operative recurrence is continued smoking. Multiple studies have shown that smokers have a dramatically higher risk of both clinical and endoscopic recurrence, and that this recurrence happens sooner and is often more severe than in non-smokers. Crucially, studies have also shown that smoking cessation after surgery significantly reduces the risk of recurrence, highlighting a critical opportunity for intervention (Reese et al., 2008; Johnson et al., 2005).

CONCLUSION

The pivotal body of scientific literature presents a clear, consistent, and damning verdict on the relationship between tobacco smoking and Crohn's disease. The evidence is unequivocal: smoking is a major risk factor for developing the disease and is the single most important modifiable factor for worsening its course. Smokers experience more aggressive and

complicated disease, respond more poorly to medical therapy, and have a much higher rate of recurrence after surgery.

This comprehensive evidence base has transformed smoking cessation from general health advice into a specific, targeted, and essential therapeutic intervention for patients with Crohn's disease. The research confirms that advising and assisting patients with Crohn's disease to quit smoking is a non-negotiable, cornerstone of effective and comprehensive management, with the potential to favorably alter the natural history of this chronic and debilitating condition.

REFERENCES

Cosnes, J., Beaugerie, L., Carbonnel, F. and Gendre, J.P. (2004) 'Smoking cessation and the course of Crohn's disease: an intervention study', *Gastroenterology*, 126(1), pp. 5-10.

Johnson, G.J., Cosnes, J. and Mansfield, J.C. (2005) 'Review article: smoking cessation as a primary therapy to modify the course of Crohn's disease', *Alimentary Pharmacology & Therapeutics*, 21(8), pp. 921-931.

Louis, E., Mary, J.Y., Vernier-Massouille, G., Grimaud, J.C., Bouhnik, Y., Laharie, D., Dupas, J.L., Pillant, H., Picon, L., Veyrac, M., Flamen, X., Quévat, D., Salmeron, M., Turin, A., Altwegg, R. and Lémann, M. (2003) 'Maintenance of remission among patients with Crohn's disease on infliximab: a randomized trial', *Gastroenterology*, 125(3), pp. 690-698.

Mahid, S.S., Minor, K.S., Soto, R.E., Hornung, C.A. and Galandiuk, S. (2006) 'Smoking and inflammatory bowel disease: a meta-analysis', *Mayo Clinic Proceedings*, 81(11), pp. 1462-1471.

Reese, G.E., Nanidis, T., Borysiewicz, C., Yamamoto, T., Orchard, T. and Tekkis, P.P. (2008) 'The effect of smoking after surgery for Crohn's disease: a meta-analysis of observational studies', *International Journal of Colorectal Disease*, 23(12), pp. 1213-1221.